Clinical and response characteristics of 15 patients with CMML enrolled in the phase 1 lenzilumab study. (A) Oncoplot demonstrating the genotype of 15 CMML patients as documented at the time of enrollment into the study and their correlation with disease responses, as adjudicated by the IWG MDS/MPN overlap syndrome response criteria. It also shows the dose cohort, number of doses of the study drug, exposure to prior therapies, and duration of response. The patient number (as indicated in Table 1) is shown below the x-axis. (B) Grades 1-4 AEs encountered in the phase 1 lenzilumab CMML study.